2 results match your criteria: "University of Ottawa Division of Medical Oncology[Affiliation]"
Low to intermediate grade lung neuroendocrine tumours. A single centre real world experience.
Cancer Treat Res Commun
December 2024
University of Ottawa Division of Medical Oncology, Ottawa, Ontario, Canada; The Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada; The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Article Synopsis
- - Lung neuroendocrine tumors (LNETs) are rare and increasingly diagnosed tumors, and this study examines their diagnosis, treatment, and survival trends among patients with low to intermediate grades.
- - A review of 59 patients revealed that surgical treatment led to significantly better five-year overall survival (83%) compared to non-surgical options (44%), although metastatic disease had a poor prognosis (39% survival for stage IV).
- - The study emphasizes that while there are multiple treatment options, the lack of established guidelines for treatment sequencing indicates a need for improved evidence-based practices in managing LNETs.
Article Synopsis
- The study aims to analyze trends in the diagnosis of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) from June 2010 to June 2021, particularly looking at any changes during the early COVID-19 pandemic.
- Out of 647 GEP-NET patients assessed, most had advanced disease at diagnosis, with the small bowel being the most common primary site, while early-stage diagnoses saw a slight increase over the decade.
- The frequency of GEP-NET diagnoses remained relatively stable, except for lower gastrointestinal cases, which notably increased after mid-2017, possibly due to the implementation of new detection methods in Ontario.